ABSTRACT

A class of novel compounds is described for use in affecting lymphatic absorption of cholesterol. Compounds of particular interest are defined by Formula I:

![Chemical Structure](attachment:image.png)

or a pharmaceutically acceptable salt thereof.

51 Claims, 4 Drawing Sheets
OTHER PUBLICATIONS


FIG. 1

\[ \text{Control} \quad \text{Compound I} \]

$^{14}$C-CH absorption (% dose/h)

Time (h)

* indicates significant difference.
FIG. 2

Oleic acid output (μmol/h)

Control

Compound I

Time (h)

1 2 3 4 5 6 7 8

0 30 60 90 120 150

*
FIG. 3

Inhibition (%)

1st

2nd
FIG. 4

Concentration (µM)

Inhibition (%)  

Concentration (µM)

Ferroverdin A
1
COMPOUNDS AFFECTING CHOLESTEROL ABSORPTION

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

Funding for the work described above herein was provided in part by the federal government, which may have certain rights in the invention. This application was supported by government funding from the following agencies: NASA under grant number CCC-131, National Institute of Health under grant number CA86842, and National Science Foundation under grant number 0078921.

TECHNICAL FIELD

This invention relates to novel organic compound and methods for their synthesis. More particularly, the invention relates to novel compounds affecting lymphatic absorption of cholesterol.

BACKGROUND

Atherosclerosis is a major cause of heart attack, stroke, and gangrene of the extremities and can be attributed directly to having high levels of cholesterol in the body. Cholesterol can enter the body by absorption from foods by the intestinal mucosal cells and the lymphatic system (i.e., exogenous sources). Cholesterol also is produced in the liver by a sequence of enzymatic reactions (i.e., endogenous biosynthesis). Endogenous biosynthesis of cholesterol involves a key enzyme, HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase. HMG-CoA reductase inhibitors can be used to lower total plasma cholesterol in patients with primary hypercholesterolemia. Effective inhibition of HMG-CoA reductase is realized by drugs such as Lovastatin (sold as Mevacor from Merck Co.), Mevalotin (from Sankyo Co., Japan), and analogs thereof (e.g., compounds sold under the trade names Sivastatin, Mevastatin, and Pravastatin). Exogenous sources of cholesterol, however, are not affected by these drugs. Various compounds have been reported to be useful for lowering cholesterol absorption. See, e.g., U.S. Pat. Nos. 5,246,960, 5,175,186, 5,215, 5,495,048, 5,856,503, and 5,637,771. Currently, a lipase inhibitor termed Xenical® has been reported to achieve a slight reduction in cholesterol.

SUMMARY

The invention features a compound of Formula I:

\[
R_1, R_2, R_3, R_4, R_5, \text{ and } R_6 \text{ can be independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfonylamyl, N-N-dialkylsulfonylamyl, N-arylsulfonylamyl, N-alkyl-N-arylsulfonylamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamidomido, N-N-dialkylamido, N-monoarylarnido, N-alkyl-N-arylarnido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminokylamino, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cyloalkenyl, alkythio, alkylsulfanyl, N-alkylaminol, N-N-dialkylamino, acyl, acyloxy, aroyloxy, acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, arylsulfenyl, arylsulfenyl, arylsulfanyl, or arylsilyloxy, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfonylamyl, N,N-dialkylsulfonylamyl, N-arylsulfonylamyl, N-alkyl-N-arylsulfonylamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamidomido, N-N-dialkylamido, N-monoarylarnido, N-alkyl-N-arylarnido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminokylamino, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cyloalkenyl, alkythio, alkylsulfanyl, N-alkylaminol, N-N-dialkylamino, acyl, acyloxy, aroyloxy, acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, arylsulfenyl, arylsulfenyl, arylsulfanyl, or arylsilyloxy).

R_4 can be independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfonylamyl, N,N-dialkylsulfonylamyl, N-arylsulfonylamyl, N-alkyl-N-arylsulfonylamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamidomido, N-N-dialkylamido, N-monoarylarnido, N-alkyl-N-arylarnido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminokylamino, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cyloalkenyl, alkythio, alkylsulfanyl, N-alkylaminol, N-N-dialkylamino, acyl, acyloxy, aroyloxy, acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, arylsulfenyl, arylsulfenyl, arylsulfanyl, or arylsilyloxy).

R_5 can be independently hydrido, halo, or hydroxyalkyl.

R_6 can be independently hydrido, alkyl, or hydroxyalkyl.

In some embodiments, R_1 is halo, R_2, and R_3 are hydroxy, and R_4 and R_5 are alkyl in the compound, e.g., R_1 is chloro and R_2 and R_3 are methyl. In other embodiments, R_1 is halo, R_2 and R_3 are alkylsilyloxy, and R_4 and R_5 are alkyl, e.g., R_1 is chloro, R_2 and R_3 are OSi-t-BuMe2, and R_4 and R_5 are methyl. In one embodiment, the compound has Formula (24):
In some embodiments, R₁ is halo, R₂ and R₃ are selected from hydroxy and alkylsilyloxy, and R₄ and R₅ are alkyl, e.g., R₁ is chloro, R₂ and R₃ are hydroxy, and R₄ and R₅ are methyl. In some embodiments, R₁ is halo, R₂ and R₃ are alkylsilyloxy, and R₄ and R₅ are methyl, e.g., R₁ is chloro, R₂ and R₃ are OSi-t-BuMe₂, and R₄ and R₅ are methyl. In some embodiments the compound has Formula (23):

\[ R₄ \] = \text{halo} \quad \text{and} \quad R₂, R₃ = \text{alkylsilyloxy} \quad \text{and} \quad R₄, R₅ = \text{methyl}.

The invention also features a compound of Formula II:

In some embodiments, R₁ is halo, R₂ and R₃ are hydroxy, and R₄ and R₅ are alkyl. In some embodiments, R₁ is halo, R₂ and R₃ are alkylsilyloxy, and R₄ and R₅ are alkyl, e.g., R₁ is chloro, R₂ and R₃ are OSi-t-BuMe₂, and R₄ and R₅ are methyl.

The invention also features a compound of Formula III:

R₁ can be independently any of the groups described above for R₁ of Formula I. R₂ can be independently any of the groups described above for R₂ of Formula I. R₃ can be independently any of the groups described above for R₃ of Formula I. R₄ can be independently hydrido, alkyl, or hydroxyalkyl.

In some embodiments, R₁ is halo, R₂ and R₃ are hydroxy, and R₄ and R₅ are alkyl. In some embodiments, R₁ is halo, R₂ and R₃ are alkylsilyloxy, and R₄ and R₅ are alkyl, e.g., R₁ is chloro, R₂ and R₃ are OSi-t-BuMe₂, and R₄ and R₅ are methyl.

The invention also features a compound of Formula IV:

In some embodiments, R₁ is halo, R₂ and R₃ are selected from hydroxy and alkylsilyloxy, and R₄ and R₅ are alkyl, e.g., R₁ is chloro, R₂ and R₃ are hydroxy, and R₄ and R₅ are methyl. In some embodiments, R₁ is halo, R₂ and R₃ are alkylsilyloxy, and R₄ and R₅ are methyl, e.g., R₁ is chloro, R₂ and R₃ are OSi-t-BuMe₂, and R₄ and R₅ are methyl. In some embodiments the compound has Formula (23):

In these compounds, R₁ can be independently any of the groups described above for R₁ of Formula I. R₂ can be independently any of the groups described above for R₂ of Formula I. R₃ can be independently any of the groups described above for R₃ of Formula I. R₄ can be independently hydrido, alkyl, or hydroxyalkyl.

In some embodiments, R₁ is halo, R₂ and R₃ are selected from hydroxy and alkylsilyloxy, or aralkyloxy, R₄ and R₅ are alkyl, R₆ is selected from hydrido, hydroxy, or acyloxy, and R₇ is selected from alkyl or arylselenylalkyl, e.g., R₁ is chloro; R₂ and R₃ are OSi-t-BuMe₂; R₄ and R₅ are methyl; R₆ is hydrido, and R₇ is methyl. In other embodiments, R₁ is chloro, R₂ and R₃ are hydroxy, R₄ and R₅ are methyl, R₆ is hydrido, and R₇ is methyl. In some embodiments, R₁ is chloro; R₂ and R₃ are aralkyloxy; R₄ and R₅ are methyl, R₆ is hydrido, and R₇ is arylkoxy. In some embodiments, R₁ is chloro; R₂ and R₃ are aralkyloxy, R₄ and R₅ are methyl, R₆ is acyloxy, and R₇ is arylkoxy. In some embodiments, R₁ is chloro, R₄ and R₅ are aralkyloxy, and R₇ is methyl.
The invention also features a compound of Formula V:

\[
\text{(V)}
\]

\[
\begin{align*}
R_1, \text{ can be independently any of the groups described above for } R_1, \text{ of Formula I. } R_2, \text{ can be independently any of the groups described above for } R_2, \text{ of Formula I. } R_3, \text{ can be independently any of the groups described above for } R_3, \text{ of Formula I. } R_4, \text{ can be independently hydrido, alkyl, or hydroxyalkyl. } R_5, \text{ is independently hydrido, alkyl, or hydroxyalkyl. } R_6, \text{ can be hydroxy. } R_7, \text{ can be independently hydrido, or alkylsilyloxy.}
\end{align*}
\]

In some embodiments, \( R_1, \) is halo; \( R_2, \) and \( R_3, \) are arylaalkyloxy; \( R_4, \) and \( R_5, \) are alkyl; \( R_6, \) is hydroxy; and \( R_7, \) is selected from hydroxy and alkylsilyloxy, e.g., \( R_1, \) is chloro; \( R_2, \) and \( R_3, \) are OBn; and \( R_4, \) and \( R_5, \) are methyl; \( R_6, \) is hydroxy; and \( R_7, \) is OSi-tBuMe₂. In some embodiments, \( R_1, \) is chloro; \( R_2, \) and \( R_3, \) are OBn; \( R_4, \) and \( R_5, \) are methyl; \( R_6, \) is hydroxy; and \( R_7, \) is hydroxy.

The invention also features a method of synthesizing a compound of Formula I:

\[
\begin{align*}
\text{(I)}
\end{align*}
\]

wherein \( R_1, \) is chloro, \( R_2, \) and \( R_3, \) are OSi-tBuMe₂, The method comprises deprotecting compound (18). The result is a compound of Formula I.

The invention also features a method of synthesizing (+) chloropuupehenone. The method comprises hydrogenating compound (19) to form compound (25).

\[
\begin{align*}
\text{(25)}
\end{align*}
\]

Desilylation of compound (25) forms compound (26).

\[
\begin{align*}
\text{(26)}
\end{align*}
\]

wherein \( R_1, \) is chloro, \( R_2, \) and \( R_3, \) are hydroxy, and \( R_4, \) and \( R_5, \) are methyl. The method comprises reacting compound (4) with compound (3) to form intermediate compound (18).

\[
\begin{align*}
\text{(4)}
\end{align*}
\]

wherein \( R_5, \) is OSi-t-BuMe₂, \( X_1, \) is chloro, \( X_2, \) is bromo;
Oxidation of compound (26) forms (+) chloropuupe-hezone (27).

The invention also features a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of Formula 1:

The composition can be in the form of a capsule or a liquid emulsion. The composition can in a controlled release formulation, e.g., a dispersion in hydroxypropylmethyl cellulose, or in a formulation suitable for parenteral administration, e.g., a lipid emulsion. The composition can comprise a diluent such as polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, or benzyl alcohol. The pharmaceutically-acceptable carrier material can be lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, povidone, polyvinylpyrrolidone, or polyvinyl alcohol.

The invention also features a method for identifying a compound that inhibits lymphatic absorption of cholesterol. The method comprises administering a known amount of cholesterol and a compound of claim 1 to a non-human mammal, and determining the amount of administered cholesterol that is absorbed by the lymph. A statistically significant decrease in lymphatic cholesterol absorption relative to the lymphatic cholesterol absorption of a corresponding control mammal indicates that the compound is effective for inhibiting lymphatic absorption of cholesterol. A statistically insignificant change or a statistically significant increase in lymphatic cholesterol absorption relative to the lymphatic cholesterol absorption of a corresponding control mammal indicates the compound does not inhibit lymphatic absorption of cholesterol. The cholesterol and the compound can be administered in a lipid emulsion.

The invention also features a method of treating a cholesterol-related condition. The method comprises administering an effective amount of a compound of Formula I to a mammal. The cholesterol-related condition can be, for example, atherosclerosis, hypercholesterolemia, heart attack, gangrene, and stroke. The compound can be administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly, or topically, and in an amount from about 4 mg/kg to about 4 g/kg of body weight per day. The compound can be administered in a composition as described above. The method can be part of a treatment regimen comprising a diet low in cholesterol, or as part of a treatment regimen that includes administering an HMG-CoA reductase inhibitors. The method can be used to treat humans. The method can include administering the compound for 7 days or more, e.g., for one year or more.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is a graph showing hourly rates of lymphatic absorption of cholesterol in lymph-cannulated rats. Values are expressed as means±SD, n=5. * Indicates a significant difference between treatments at p<0.05.

FIG. 2 is a graph showing hourly rates of lymphatic absorption of oleic acid in lymph-cannulated rats. Values are expressed as means±SD, n=5. * Indicates a significant difference between treatments at p<0.05.

FIG. 3 is a graph showing percent inhibition of cholesterol ester transfer protein (CETP) activity in the presence of various concentrations of compound 24. The results from two replicates of the assay are shown.

FIG. 4 is a graph showing percent inhibition of CETP activity in the presence of various concentrations of Ferroverdin A.

DETAILED DESCRIPTION

Compounds of Formula I

A class of compounds useful for inhibiting lymphatic absorption of cholesterol is defined by Formula I:

wherein R₁ is selected from hydrido, halo, alkyl, alkenyl, alkylidy, haloalkyl, hydroxyalkyl, hydroxy, alkoxy,
within Formula II, pharmaceutically acceptable salts thereof as follows:

A second class of compounds is defined by Formula II:

\[
\begin{align*}
\text{Compounds of Formula II} & \\
\text{wherein } R_5 & \text{ is selected from moieties described above for } R_5 \text{ groups of Formula I, } R_4 & \text{ is selected from the moieties described above for } R_4 \text{ groups of Formula I, } R_3 & \text{ is selected from hydrido, alkyl, and hydroxyalkyl, and } R_2 & \text{ is selected from hydrido, alkyl, and hydroxyalkyl.}
\end{align*}
\]

A family of specific compounds of particular interest within Formula II consists of compounds and their pharmaceutically acceptable salts as follows:

\[
\begin{align*}
\text{Compounds of Formula III} & \\
\text{wherein } R_1 & \text{ is selected from moieties described above for } R_1 \text{ groups of Formula I, } R_2 & \text{ is selected from the moieties described above for } R_2 \text{ groups of Formula I, } R_3 & \text{ is selected from hydrido, alkyl, and hydroxyalkyl, and } R_4 & \text{ is selected from hydrido, alkyl, and hydroxyalkyl.}
\end{align*}
\]

A family of specific compounds of particular interest within Formula I includes compounds and their pharmaceutically acceptable salts thereof as follows:

\[
\begin{align*}
\text{(4aS,6aR,12bS)-2H-9,10-Bis-(t-butyldimethylsilyloxy)-11-chloro-1,3,4,4a,5,6,6a,12b-octahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene (18).}
\end{align*}
\]
A family of specific compounds of particular interest within Formula III includes compounds and their pharmaceutically acceptable salts as follows:

\[(4aS,6aR,12aR,12bS)-2H-9,10-Bis-(1-butylidimethylsilyloxy)-11-chloro-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene (21);\]

and

\[(4aS,6aR,12aR,12bS)-2H-11-Chloro-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene-9,10-diol (22).\]

A second family of specific compounds of particular interest within Formula III includes oxidation products and their pharmaceutically acceptable salts as follows:

\[(4aS,6aR,12aR,12bS)-2H-11-Chloro-1,3,4,4a,5,6,6a,9,10,12a,12b-dodecahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene-9,10-dione (23);\]

and

\[(4aS,6aR,12aR,12bS)-2H-11-Chloro-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene-9,10-diol (22).\]

Compounds of Formula IV

A fourth class of compounds is defined by Formula IV:

\[
[IV]
\]

wherein \(R_1\) is selected from the moieties described above for \(R_1\) groups of Formula I, \(R_2\) is selected from the moieties described above for \(R_2\) groups of Formula I, \(R_3\) is selected from the moieties described above for \(R_3\) groups of Formula I, \(R_4\) is selected from hydrido, alkyl, and hydroxyalkyl, \(R_5\) is selected from hydrido, alkyl, and hydroxyalkyl, \(R_6\) is selected from hydrido, hydroxy, and acyloxy, and \(R_7\) is selected from alkyl and arylselenylalkyl. The class of compounds also includes pharmaceutically acceptable salts thereof.

An exemplary class of compounds includes those compounds of Formula IV wherein \(R_1\) is halo, \(R_2\) is selected from hydroxy, alkylsilyloxy, and aralkyloxy; \(R_3\) is selected from hydroxy, alkylsilyloxy, and aralkyloxy; \(R_4\) is selected from hydrido, alkyl, and hydroxyalkyl; \(R_5\) is selected from hydrido, hydroxy, and acyloxy; \(R_6\) is selected from alkyl and arylselenylalkyl; \(R_7\) is selected from alkyl and arylselenylalkyl. A family of specific compounds of particular interest within Formula IV includes the following compounds and their pharmaceutically acceptable salts as follows:

\[(4aS,6aR,12aR,12bS)-2H-9,10-Bis-(1-butylidimethylsilyloxy)-11-chloro-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene (25); (4aS,6aR,12aR,12bS)-2H-11-Chloro-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene-9,10-diol (26); (4aS,6aR,12aS,12bS)-2H-9,10-Bis(benzyloxy)-11-chloro-hydroxy-6a-(phenylselenylmethyl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,12b-trimethyl-benzo[a]xanthene (40); (4aS,6aR,12aS,12bS)-2H-12-Acetoxy-9,10-bis(benzyloxy)-11-chloro-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene (42).\]

Compounds of Formula V

A fifth class of compounds is defined by Formula V:

\[
[V]
\]

wherein \(R_1\) is selected from the moieties described above for \(R_1\) groups of Formula I, \(R_2\) is selected from the moieties described above for \(R_2\) groups of Formula I, \(R_3\) is selected from the moieties described above for \(R_3\) groups of Formula I, \(R_4\) is selected from hydrido, alkyl, and hydroxyalkyl, \(R_5\) is selected from hydrido, alkyl, and hydroxyalkyl, \(R_6\) is selected from hydrido, alkyl, and hydroxyalkyl, \(R_7\) is selected from hydrido, hydroxy, and acyloxy, and \(R_8\) is selected from hydrido, hydroxy, and acyloxy. The class of compounds also includes pharmaceutically acceptable salts thereof.

An exemplary class of compounds includes those compounds of Formula V wherein \(R_1\) is halo; \(R_2\) is selected from hydroxy, alkylsilyloxy and aralkyloxy; \(R_3\) is selected from hydroxy, alkylsilyloxy, and aralkyloxy; \(R_4\) is selected from hydrido, alkyl, and hydroxyalkyl; \(R_5\) is selected from hydrido, alkyl, and hydroxyalkyl; \(R_6\) is selected from hydroxy, and \(R_8\) is selected from hydroxy and alkylsilyloxy. A family of specific compounds of particular interest within Formula V includes the following compounds and their pharmaceutically acceptable salts as follows:

\[(4aS,8aS)-1\{[2-chloro-3,4-dibenzyloxy-6-(1-butylidimethylsilyloxy)phenylhydroxymethyl]-2-methylene-5,5,8a-trimethyldecahydronaphthalene (37);\]

and

\[(4aS,8aS)-1\{[2-chloro-3,4-dibenzyloxy-6-hydroxy]phenylhydroxymethyl]-2-methylene-5,5,8a-trimethyldecahydronaphthalene (38).\]

The term “alkyl” embraces linear or branched saturated aliphatic radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about four carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, cyclohexyl, cyclopentyl, cyclohexyl, cyclohexyl and cyclooctyl, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
The term alkyl includes both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxyacyronxyloxy, aryloxyacyronxyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminoacarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxycarbonyl, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, dialkyaminocarbonyl, and dialkyaminocarboxyl), acylaminino (including alkylcarbonylaminino, arylcarbonylaminino, carbamoyl and ureido), amidino, imino, sulfonyl, alkylthio, aroylthio, thiocarboxylate, sulfates, sulfinyl, alkoxycarbonyl, sulfamoyl, sulfonato, sulfamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkenyl, and alkynyl radicals. The term “carbonyl” embraces radicals having a carboxy radical as defined above, specifically embraced are monohalocarboxylic, dihalocarboxylic and polyhalocarboxylic radicals. A monohalocarboxylic radical, for one example, may have either a bromo, chloro or a fluoro atom within the radical. Dihalo radicals may have two or more of the same halo atoms or a combination of different halo radicals and polyhalocarboxylic radicals may have more than two of the same halo atoms or a combination of different halo radicals. The term “hydroxylalkyl” embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. The terms “alkoxy” and “alkoxyalkyl” embrace linear or branched oxy-containing radicals. Examples of unsaturated hydroxylalkyl radicals having two or more alkyl radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The “alkoxy” or “alkoxyalkyl” radicals may be further substituted with one or more halo atoms, such as chloro or bromo to provide haloalkoxyalkyl radicals. Examples of “alkoxy” radicals include methoxy and ethoxy radicals. The term “heteroaryl” embraces aromatic radicals such as phenyl, naphthyl, tetrahidronaphthyl, indane and biphenyl. The term “heterocyclic” embraces saturated, partially saturated and unsaturated heteroatom-containing ring-shaped radicals, where the heteroatom may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclic radicals include pyrrolidyl and morpholinyl. The term “heteroaryl” embraces unsaturated heteroatom-containing radicals. Examples of unsaturated heterocyclic radicals, also termed “heteroaryl” radicals include thienyl, pyrryl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, pyridyl and tetrazolyl. The term also embraces radicals where heterocyclic radicals are fused with aryl radicals. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like. The term “sulfonil”, whether used alone or linked to other terms such as alkylsulfonil, denotes respectively divalent radicals —SO₂—N₄—. “Alkylsulfonil” embraces alkyl radicals attached to a sulfonil radical, where alkyl is defined as above. The term “arylsulfonil” embraces sulfonil radicals substituted with an aryl radical. The terms “sulfonyl” or “sulfonamidyld”, whether alone or used with terms such as “N-alkysulfonyl”, “N-arylsulfonyl”, “N,N-dialkysulfonyl” and “N,N-dialkylsulfonyl”, denotes a sulfonil radical substituted with an amine radical, forming a sulfonamide (—SO₂-NH₂). The terms “N-alkysulfonyl” and “N,N-dialkylsulfonyl” denote sulfonyl radicals substituted, respectively, with one alkyl radical, a cycloalkyl ring, or two alkyl radicals. The terms “N-arylsulfonyl” and “N,N-dialkylsulfonyl” denote sulfonamidyld radicals substituted, respectively, with one aryl radical, and one alkyl and one aryl radical. The terms “carboxy” or “carbonyl”, whether used alone or with other terms, such as “carboxylic”, denotes —CO₂H. The term “carboxyalkyl” embraces radicals having a carboxy radical as defined above, attached to an alkyl radical. The term “carbonyl”, whether used alone or with other terms, such as “alkylcarbonyl”, denotes —(C=O)—. The term “alkylcarbonyl” embraces radicals having a carboxy radical substituted with one, two or three alkyl radicals. An example of an “alkylcarbonyl” radical is CH₃—(C=O)—. The term “alkylcarbonylalkyl” denotes an alkyl radical substituted with an “alkylcarbonyl” radical. The term...
“alkoxy carbonyl” means a radical containing an alkoxy carbonyl as defined above, attached via an oxygen atom to a carbonyl (C=O) radical. Examples of such “alkoxy carbonyl” radicals include (CH₃)₂CO—C(==O)— and —(O=)C—OCH₃. The term “alkoxy carbonylalkyl” embrace radicals having “alkoxy carbonyl”, as defined above substituted to an alkyl radical. Examples of such “alkoxy carbonylalkyl” radicals include (CH₃)₃COCC(==O)(CH₂)₄— and —(CH₂)₅(O=)COCH₃. The term “amido” when used by itself or with other terms such as “amidoalkyl”, “N,N-monoaryl amido”, “N,N-dialkylamido”, “N,N-dialkyl amido” and “N,N-alkylamido” embraces a carbonyl radical substituted with an amino radical. The terms “N-alkylamido” and “N,N-dialkylamido” denote amido groups which have been substituted with one alkyl radical and with two alkyl radicals, respectively. The terms “N,N-monoaryl amido” and “N,N,alkyl-N-aryl amido” denote amido radicals substituted, respectively, with one aryl radical, and one alkyl and one aryl radical. The term “N-alkyl-N-hydroxymido” embraces amido radicals substituted with a hydroxyl radical and with an alkyl radical. The term “N-alkyl-N-hydroxymidoalkyl” embraces amido radicals substituted with an amino radical. The term “amidino” embraces radicals substituted with an amino radical. The term “amidoalkyl” embraces alkyl radicals substituted with an amino radical. The term “amidinoalkyl” embraces aminoalkyl radicals having the nitrogen atom substituted with an alkyl radical. The term “amido” denotes —C(==N)—NH—. The term “cyanamido” denotes —C(==N)—NH₂. The term “het-eryocycloalkyl” embraces heterocyclic-substituted alkyl radicals such as pyridylmethyl and thienylmethyl. The term “aralkyl” embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenethyl, and diphenethyl. The terms benzyl and phenethyl are interchangeably. The term “cycloalkyl” embraces radicals having three to ten carbon atoms, such as cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The term “cycloalkenyl” embraces unsaturated radicals having three to ten carbon atoms, such as cyclopropenyl, cyclobutenyl, cyclopentenyl cyclohexenyl and cycloheptenyl. The term “cycloalkynyl” embraces radicals containing an alkynyl or branched alkynyl radical of one to ten carbon atoms, attached to a divalent sulfur atom. The term “aryl sulfenyl” embraces aryl radicals attached to a divalent sulfur atom (—S—AR). An example of “alkylthio” is methylthio, (CH₃S—). The term “alkylsulfanyl” embraces radicals containing a linear or branched alkynyl radical of one to ten carbon atoms, attached to a divalent sulfanyl atom. The term “arylsulfenyl” embraces aryl radicals attached to a divalent sulfanyl atom (—S—AR). The terms “N-alkylamino” and “N,N-alkylamido” denote amine groups which have been substituted with one alkyl radical and with two alkyl radicals, respectively. The term “acyl”, whether used alone, or within a term such as “acylamino”, denotes a radical provided by the residue after removal of hydroxyl from an organic acid. The term “acylamino” embraces an amine radical substituted with an acyl group. An example of an “acylamino” radical is acetamyl (CH₃C(==O)—NH—). The term “aryloxy” denotes a radical provided by the residue after removal of hydroxy from an hydroxy-substituted aryl moiety (e.g., phenol). The term “alkylsilyl” denotes a silyl radical substituted with an alkyl group. The term “alkylsilyloxy” denotes a silyloxy radical (—O—SiR₃) substituted with an alkyl group. An example of an “alkylsilyloxy” radical is —OSi—t-BuMe₂. The term “arylselenyl” denotes an selenyl radical substituted with a selenylaryl group. An example of an “arylselenylalkyl” radical is —CH₂SePh.

“pharmaceutically-acceptable salts” embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be obtained from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfamic and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, maleic, malic, tartaric, citric, ascorbic, glucuronic, malic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenoylecetate, mandelic, embolic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, fumaric, tartaric, ethanesulfonic, p-hydroxybutyric, salicylic, galactaric and galacturonic acid.

Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of Formula I, II, III, IV, or V by reacting, for example, the appropriate acid or base with the compound of Formula I, II, III, IV, or V.

Pharmaceutical Compositions

The present invention includes a pharmaceutical composition for inhibiting lymphatic absorption of cholesterol, comprising a therapeutically-effective amount of a compound of Formula I in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent.

A pharmaceutical composition comprises one or more compounds of Formulae I-V in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as “carrier” materials) and, if desired, other active ingredients. A compound of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. A compound may, for example, be administered orally, intravenously, intraperitoneally, subcutaneously, intramuscularly or topically.

For oral administration, a pharmaceutical composition may be in the form of, for example, a tablet, capsule, emulsion, suspension or solution. A pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier.

The amount of therapeutically active compound that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the sever-
utilized in the treatment of cholesterol-related conditions in
polyvinylpyrrolidone, and/or polyvinyl alcohol, and then
various buffers. Other adjuvants and modes of administra-
tion are well and widely known in the pharmaceutical art.
Methods
Compounds of Formula I and related compounds can be
utilized in the treatment of cholesterol-related conditions in
mammals, including humans, dogs and cats. Cholesterol-
related conditions include, for example, atherosclerosis, hyper-
cholesterolemia, heart attack, stroke, and gangrene of
the extremities. A method of treatment includes administer-
ing an effective amount of a compound of Formula I. The
method of treatment includes administering an effective amount of a compound of Formula I. The
compound can be administered as a pharmaceutical
composition, as described above. A compound of the present
invention can be administered by any suitable route, typi-
cally in the form of a pharmaceutical composition adapted to
such a route, and in a dose effective for the treatment
intended. A compound may, for example, be administered orally, intravenously, intraperitoneally, subcutaneously,
intramuscularly or topically.

The amount of compound that is administered and the
dosage regimen for treating a disease condition with the
compounds and/or compositions of this invention depends on
a variety of factors and can be determined by an attending
physician. These factors include the age, body weight, sex
and medical condition of the subject, the severity of the
disease, the route and frequency of administration, the
particular compound employed, health status, diet, other
medications, and other relevant clinical factors. The amount
of compound administered can range from about 4 mg/kg
body weight per day to about 4 g/kg of body weight per day.
For example, a compound can be administered at a daily
dose of 5 mg/kg, 10 mg/kg, 100 mg/kg, 250 mg/kg, 1000
mg/kg, 1500 mg/kg, 2000 mg/kg, or 3000 mg/kg. The daily
dosage can be administered once per day, twice per day,
three times per day, or four or more times per day. Variations
in these dosage levels can be adjusted using standard empiri-
cal routines for optimization.

The concentration of a compound of the present invention
effective to treat a cholesterol-related condition in a mammal
may vary, depending on a number of factors, including the
preferred dosage of the compound to be administered, the
chemical characteristics of the compounds employed, the
formulation of the compound excipients and the route of
administration. The optimal dosage of a pharmaceutical
composition to be administered may also depend on such
variables as the overall health status of the particular patient
and the relative biological efficacy of the compound
selected. The amount and dosage regimen effective for
treating a cholesterol-related condition in a mammal can be
determined by, e.g., measuring cholesterol levels prior to the
start of treatment and at various times after treatment has
commenced. Assays for the quantitation of cholesterol are
known, including assays for the level of cholesterol in blood
or lymph. Administration of an effective amount results in a
decrease in lymphatic absorption of cholesterol that is
statistically significant at a p<0.05 with an appropriate
parametric or non-parametric statistic, e.g., Chi-square test,
Student’s t-test, Mann-Whitney test, or F-test. In some
embodiments, a difference in cholesterol level is statistically
significant at p<0.01, p<0.005, or p<0.001.

A compound of the present invention can be administered
as a single dose or can be administered for a period of from
de one day to many years, e.g., for 3 days or more, for 7 days
or more, for 14 days or more, for 30 days or more, for one
year or more, or for 3 years or more. The duration of the
administration period depends upon, e.g., the daily dosage,
the type of cholesterol-related condition and the patient’s
response to the compound.

A compound of the present invention can be administered
in conjunction with a diet low in cholesterol as part of a
cholesterol lowering treatment regime. A compound of the
present invention also can be administered in conjunction
with drugs such as Lovastatin (sold as Mevacor from Merck
Co.), Mevalotin (from Sankyo Co., Japan), and analogs
thereof (e.g., compounds sold under the trade names Sivastatin, Mevatin, and gancotrol that is licensed for
cholesterol levels and to prevent and treat cholesterol-related
conditions, e.g., hypercholesterolemia. A compound of the
invention also can be administered in conjunction with Xenical®, a prescription medication offered for use in
weight loss regimens.

Compounds of Formulae I-V also can be tested for their
effect on lymphatic absorption of dietary cholesterol. Meth-
ods for measuring lymphatic absorption of cholesterol in vivo are known. A suitable in vivo method is described in

Typically, a method of measuring inhibition of cholesterol
absorption in vivo involves administering a predetermined
amount of cholesterol and a test compound of Formulae I-V
to the intestine of a mammal. Typically, the animal is a fasted
mammal. The cholesterol and test compound can be admin-
istered in a lipid emulsion into the duodenum of the mammal
over a period of a few hours. Suitable non-human mammals
include rats, mice, guinea pigs, and hamsters. The amount of
administered cholesterol that appears in the mesenteric
lymph of the mammal is determined at various times during
and after administration, typically at hourly intervals. The
amount of cholesterol present in the lymph is compared to
the amount present in a control animal that has had chole-
sterol but no test compound administered. If the amount of
cholesterol appearing in the lymph of the test animal is
statistically significantly less than the amount of cholesterol
in the lymph of the control animal, it is concluded that the
compound can inhibit intestinal absorption of cholesterol.

General Synthetic Procedures
The compounds of the invention can be synthesized
according to the procedures of Schemes 1–6, wherein the
R₁–R₈ substituents are as defined for Formulae I-V, above,
except where further noted.
Scheme 1 shows the synthesis of enantiopure A-B fragment 3 from commercially available 3αR-(+)-sclareolide 5 (purchased from Aldrich Chemical Company). Deprotonation of optically pure lactone 5 with LDA (lithium diisopropylamide) in THF at -78°C, followed by treatment with MoO₃-pyrine/HMPA complex gave two diasteromers, 6 (65.6% yield) and 7 (12.4% yield) (which were separated by silica gel chromatography), along with 20% recovery of starting scclareolide 5. Treatment of a mixture of 6 and 7 with lithium aluminum hydride in THF at room temperature gave triol 8 (70% yield) and lactol 9 (30% yield). Oxidative cleavage of 8 with lead tetraacetate in benzene at 25°C provided an 90% yield of 10, and oxidative cleavage of 9 under similar conditions gave an 85% yield of 11. Dehydration of alcohol 10 with p-toluenesulfonic acid in refluxing toluene for 2 h gave a 78% yield of enal 3. Basic hydrolysis of the formyl ester group of 11 with potassium carbonate in methanol at 0°C provided a 92% yield of 10, which was converted into 3, as described above. The preparation of compound 3 from (-)-sclareol using a different synthetic method has been reported previously (Reeves, P. G. (1996).

Scheme 2 shows the preparation of D-ring fragment 4 starting from 3-chlorovanillin 12, derived from the chlorination of vanillin with chlorine in acetic acid (85% yield), according to the procedure of Ham et al. (J. Am. Chem. Soc., 1927, 49, 535-7). Demethylation of 12 with BB₃ in CH₂Cl₂ (94% yield) followed by protection of the diol with t-butyldimethylsilyl chloride, triethylamine, 4-dimethylaminopyridine (DMAP) gave aldehyde 13 (93% yield) (Jong, T. T.; Williard, P. G.; Porwoll, J. P.; J. Org. Chem., 1984, 49, 735-6). Baeyer-Villiger oxidation of 13 with m-chloroperbenzoic acid (MCPBA) in methylene chloride (70% yield) followed by basic hydrolysis with potassium carbonate (90% yield) and silylation of the resulting phenol with t-butyldimethylsilyl chloride (83% yield) provided trisilyl ether 14. Selective C4 (less hindered site compared with C6) bromination of 14 with N-bromosuccinimide (NBS) in N,N-dimethylformamide (DMF) at 25°C gave an 67% yield of 4 as the sole product; no C6 isomer 15 was isolated. Interestingly, when the bromination was carried out at 50°C, a 2:1 ratio of 15 and 4 was obtained.

Alternatively, compound 4 was also obtained from the bromination of phenol 16 (obtained from 13 with MCPBA and potassium carbonate) with N-bromosuccinimide (NBS) in DMF to give a 70% yield of bromide 17. Silylation of 17 with t-butyldimethylsilyl chloride afforded a 99% yield of 4.
When the NBS reaction was carried out at 50°C, a 2:1 ratio of 15 & 4 was obtained. Scheme 3 shows a procedure for preparing compounds embraced by Formulae I and II from enantiopure A-B fragment 3 and D-ring fragment 4. Treatment of 4 with 2 equiv of t-BuLi in diethyl ether at -78°C followed by aldehyde 3 afforded a mixture of two stereoisomers at C6a, 18 (45% yield) and 19 (9.1% yield). Removal of the silyl ether protecting groups of 18 and 19 separately gave compound 1 (82% yield) and compound 2 (81.4% yield), respectively. Spectral data of compound 2 was identical with those reported (Nasu, S. S.; Yeung, B. K. S.; Hamann, M. T.; Scheuer, P. J.; Kelly-Borges, M.; Goins, K., J. Org. Chem. 1995, 60, 7290–7292).
Scheme 4 shows the preparation of compounds embraced by Formulae 111, IV, and VI. Selective hydrogenation of 18 with 1 atmosphere of hydrogen in the presence of palladium/carbon in ethanol gave a 99% yield of tetracyclic pyran 21 as a single diastereomer (Scheme 4a). Removal of the silyloxy protecting group of 21 with tetra-n-butylammonium fluoride in THF afforded an 83% yield of diol 22.

Oxidation of diol 22 with pyridinium dichromate (PDC) in dichloromethane gave a mixture of quinones 23 and 24 in a ratio of 6:1. Quinone structures 23 and 24 were assigned based on $^1$H NMR spectrum.

Similarly, hydrogenation of 19 with 1 atmosphere of hydrogen and palladium/carbon (90% yield) followed by desilylation with tetra-n-butylammonium fluoride in THF (31% yield) and oxidation with pyridinium dichromate afforded (+)-chloropuupehenone (27) in 50% yield.
Schemes 5 and 6 show a procedure for preparation of C6a-S tetracyclic pyran compounds embraced by Formulae IV and V. Scheme 5 shows the preparation of (1R,4aS,6aS)-2,5,5,8a-tetramethyl-1,4,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxaldehyde (33) and (1R,4aS,6aS)-2-Methylene-5,5,8a-trimethyl-1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene-1-carboxaldehyde (35). Reduction of aldehyde 10 with lithium aluminum hydride in diethyl ether at 0°C, produced a 97% yield of diol 28. Silylation of the less hindered primary alcohol of 28 with t-butyldimethylsilyl chloride and imidazole in DMF gave alcohol 29 (98% yield). Elimination of 29 with methanesulfonyl chloride (MsCl) and triethylamine in dichloromethane afforded a mixture of alkenes 30 and 31 (1:1; 90% yield), which were separated by silica gel column chromatography. Desilylation of 30 with tetra-n-butylammonium fluoride in THF (88% yield) followed by oxidation with Dess-Martin Periodinane in dichloromethane provided aldehyde 33 (67% yield). Similarly, silyl ether 31 was converted to aldehyde 35 under similar reaction conditions.
Referring to synthetic Scheme 6, Bromide 36 was synthesized from the dibenzylolation of 3,4-dihydroxy-5-chlorobenzaldehyde (see Scheme 2) with NaH and benzyl chloride in THF followed by a similar reaction sequence described for the synthesis of 4 from 13. Treatment of bromide 36 with 1.1 equivalent of t-butyllithium in diethyl ether at -78°C, followed by 1 equivalent of aldehyde 35 gave alcohol 37 (62% yield), which was desilylated with n-Bu₄NF in THF to give alcohol 38 (63% yield). Ring closure of 38 with phenylselenylphthalimide and tin tetrachloride in dichloromethane afforded tetracyclic pyran 40 (50% yield) with the C6a-S configuration. The phenylselenyl reagent approaches C6a exo double bond from the opposite face of C12a alkyl group and C7 oxygen attacks the carbocation from the opposite side of the selenium ion to give 40 as the major product. Acetylation of 40 with acetic anhydride and pyridine in dichloromethane (89% yield) followed by removal of the selenyl function with AIBN (2,2'-azobisisobutyronitrile) and tri-n-butyltin hydride in refluxing toluene gave pyran 42 (90% yield). Removal of the hydrogen and palladium-carbon in methanol provided diol 26, which has identical proton NMR spectrum as that obtained in Scheme 4.
EXAMPLES

Nuclear magnetic resonance spectra were obtained at 400 MHz for 1H and 100 MHz for 13C in deuteriochloroform, and reported in ppm. Elemental analysis data were obtained from Desert Analytics, Tucson, Ariz., USA, and are reported as % C and % H. Mass spectra were taken from a Hewlett Packard 5890A Series II, GC-MS. Davisil silica gel, grade 643 (200-425 mesh), was used for the flash column chromatographic separation. Tetrahydrofuran and diethyl ether were purchased either from Aldrich Chemical Company or Fisher Chemical Company, and were used without further purification.

Example 1

(4aS,8aS)-3,4a,5,6,7,8,8a-Octahydro-2,5,5,8a-tetramethylnaphthalene-1-carboxaldehyde

Step 1: Preparation of (1S,3aR,5aS,9aS,9bR)-1-Hydroxycycloheptadecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan-2-one (6) and (1R,3aR,5aS,9aS,9bR)-1-Hydroxycycloheptadecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan-2-one (7)

To a cold (~78°C) solution of 1.02 mL (7.79 mmol) of disopropylamine in 40 mL of THF under argon, was added 6.36 mL (7.19 mmol) of n-BuLi (1.6 M in hexane). The solution was stirred at ~78°C for 1 h, and a solution of 1.50 g (5.99 mmol) of (4a)-sclareolide 5 in 20 mL of THF was added via cannula dropwise. After the solution was stirred at ~78°C for 1 h, the solution was added to 5.0 mL (0.012 mol) of MoO3, pyridine, HMPA, and stirred for 30 minutes. The mixture was diluted with saturated aqueous Na2SO4, extracted three times with ethyl acetate, and the organic layer was washed with water, and brine, dried (Na2SO4), concentrated, and column chromatographed on silica gel using a mixture of hexane/ether (9:1) as an eluent to give 1.045 g (65.6% yield) of compound 6 and 0.195 g (12% yield) of compound 9 along with 0.296 g (20% recovery) of 13C NMR (CDCl3) δ 179.0 (s, C=O), 83.5, 68.7, 64.2, 56.4, 42.3, 39.4, 39.3, 36.9, 33.4, 33.2, 23.5, 21.1, 20.7, 18.1, 15.9. Compound 7: [α]25D = -19.1° (c 0.01, CHCl3); 1H NMR (CDCl3) δ 4.37 (dd, J = 5.6, 3.2 Hz, 1H, CHO, equatorial), 2.32 (dd, J = 3.2 Hz, 1H, OH), 2.06 (dd, J = 12 Hz, 1H, 1H) and 1.89-0.98 (m, 10H, 1H, Me), 1.21 (s, 3H, Me), 0.87 (s, 3H, Me), 0.85 (s, 3H, Me); 13C NMR (CDCl3) δ 177.6 (s, C=O), 88.8, 70.2, 62.6, 57.8, 42.4, 39.8, 38.7, 37.3, 27.1, 25.2, 21.1, 20.8, 18.3, 17.3.

Step 2: Preparation of 1-(1S,1,2-Dihydroxymethyl)-(1R,2R,4aS,8aS)-Decahydro-2,5,5,8a-tetramethylnaphthalen-2-ol (8S) and (1S,3aR,5aS,9aS,9bR)-Decahydro-3a,6,6,9a-tetramethylnaphthoph[2,1-b]furan-1,2-diol (9S)

The following representative method describes the reduction of 6 and 7 to triol 8 and lactol 9. A solution of 0.90 g (3.4 mmol) of 6 in 20 mL of THF under argon, was added 0.66 g (17.3 mmol) of LiAlH4, and the mixture was stirred for 4 h at 25°C. To it, 60 mL of water and 16 mL of 1 M HCl were added, and the solution was extracted with diethyl ether three times (50 mL each). The combined ether extracts were washed with brine, dried (MgSO4), concentrated, and the resulting solid was recrystallized from hexane/ether to give 0.65 g (71% yield) of triol 8 and 0.273 g (30% yield) of lactol 9S. Compound 8: [α]25D = -7.2° (c 0.008, CH2OH); 1H NMR (CDCl3) δ 4.53 (m, 1H, CHO), 4.06 (dd, J = 10, 6 Hz, 1H, CH2O), 3.64 (dd, J = 10, 4 Hz, 1H, CH2O), 1.95 (d, J = 4 Hz, 1H), 1.70-1.01 (m, 11H), 1.43 (s, 3H, Me), 1.10 (s, 3H, Me), 0.90 (s, 3H, Me), 0.82 (s, 3H, Me); 13C NMR (CDCl3) δ 82.9, 75.2, 71.8, 68.8, 48.7, 42.4, 38.4, 33.4, 34.9, 33.7, 33.2, 28.3, 23.0, 21.9, 20.0, 18.5. Compound 9S as a mixture of 2 diastereomers at C2; 1H NMR (CDCl3) δ 5.38 (broad s, 1H), 5.33 (s, 1H), 4.35 (t, J = 5 Hz, 1H, 2H, CHO); 'H NMR (CDCl3) δ 5.22 (d, J = 3 Hz, 1H, CHO); 13C NMR (CDCl3) δ 5.22 (d, J = 3 Hz, 1H, CHO), 4.91 (d, J = 2 Hz, 1H, CHO).

Step 3: Preparation of 1R,2R,4aS,8aS)-Decahydro-2-hydroxy-2,5,5,8a-tetramethylnaphthalen-1-carboxaldehyde (10)

To a solution of 0.65 g (2.4 mmol) of a mixture of triol 8S and 8R in 25 mL of benzene under argon was added 1.3 g (9.2 mmol) of lead tetraacetate. After stirring at 25°C for 4 h, the mixture was diluted with diethyl ether, the organic layer was washed with water, and brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as the eluent to give 0.69 g (71% yield) of compound 10 along with 0.195 g (12% yield) of compound 9 along with 0.296 g (20% recovery) of Compound 9: [α]25D = -97.1° (c 0.01, CHCl3); 1H NMR (CDCl3) δ 4.48 (d, J = 12 Hz, 1H, CHO, axial), 2.06 (d, J = 12 Hz, 1H, Cβ-axial H), 1.95-1.06 (m, 11H), 1.38 (s, 3H, Me), 1.03 (s, 3H, Me), 0.88 (s, 3H, Me), 0.84 (s, 3H, Me); 13C NMR (CDCl3) δ 179.0 (s, C=O), 83.5, 68.7, 64.2, 56.4, 42.3, 39.4, 39.3, 36.9, 33.4, 33.2, 23.5, 21.1, 20.7, 18.1, 15.9. Compound 10: [α]25D = -19.1° (c 0.01, CHCl3); 1H NMR (CDCl3) δ 4.37 (dd, J = 5.6, 3.2 Hz, 1H, CHO, equatorial), 2.32 (dd, J = 3.2 Hz, 1H, OH), 2.06 (dd, J = 12 Hz, 1H, 1H) and 1.89-0.98 (m, 10H, 1H, Me), 1.21 (s, 3H, Me), 0.87 (s, 3H, Me), 0.85 (s, 3H, Me); 13C NMR (CDCl3) δ 177.6 (s, C=O), 88.8, 70.2, 62.6, 57.8, 42.4, 39.8, 38.7, 37.3, 27.1, 25.2, 21.1, 20.8, 18.3, 17.3.
were added. After the solution was reflux for 2 h, the J=13Hz, lH), 2.26 (dd, J=8, 4 Hz, lH), 2.03 J=3Hz, 1H, CHO), 2.93 (broad
37.8, 36.7, 36.4, 33.6, 33.5, 33.2, 21.8, 20.4, 19.1, 18.5. over 30 minutes (with a slow gas flow) at 25°C. White solid
solution was cooled to 25°C, diluted with saturated aque-
acordaldehyde (11) added 40 mL of methanol and methanol and trimethyl borate
37.5, 33.5, 30.5, 25.4, 21.5, 20.0, 18.3, 17.7. concentrated, and column chromatographed on silica gel
material was used in next step without purification. ‘H NMR
3.14. In a larger-scale synthesis of 3, the product was
distilled under reduced pressure to give colorless oil; bp. 60
distilled product was used in next step. [a]2zD=+520 (c 1, Step 1: Preparation of 3-Chloro-4-hydroxy-5-
thalamene-1-carboxaldehyde (10)
To a flask equipped with a Dean-Stark apparatus under argon, 10 mg (0.042 mmol) of aldehyde 10, 10 mL of toluene, and 3 mg (0.017 mmol) of p-toluenesulfonic acid were added. After the solution was reflux for 2 h, the solution was cooled to 25°C, diluted with saturated aqueous sodium bicarbonate, and extracted three times with ethyl acetate. The combined extracts were washed with brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as eluent to give 7.2 mg (78% yield) of aldehyde 3.14.

Example 2
Preparation of (1R,2R,4aS,8aS)-Decahydro-2-hydroxy-2,5,5,8a-tetramethylnapthalene-1-carboxaldehyde (11)
To a solution of 0.30 g (1.1 mol) of lactols 9S and 9R in 15 mL of benzene under argon was added 0.60 g (1.3 mmol) of lead tetraacetate. After the mixture was stirred at 25°C for 4 h, it was diluted with diethyl ether, the organic layer was washed with water and brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluent to give 0.25 g (85% yield) of aldehyde 11. [α]D 25 = -54.4° (c 0.25, CHCl3); 1H NMR (CDCl3) δ 8.02 (d, J=4Hz, 1H, CHO), 7.92 (s, 1H, OCHO), 2.55 (dd, J=9.6, 3.2Hz, 1H, C4a-H), 2.49 (d, J=4Hz, 1H, Cl-H), 1.85 (s, 3H, Me), 1.84–0.90 (m, 10H), 1.18 (s, 3H, Me), 0.83 (s, 3H, Me); 13C NMR (CDCl3) δ 204.2 (C=O) = 160.1 (C=O), 158.9, 152.2, 124.3, 21.6, 21.5, 20.0, 18.1, 17.2.

Step 2: Preparation of (1R,2R,4aS,8aS)-Decahydro-2-hydroxy-2,5,5,8a-tetramethylnapthalene-1-carboxaldehyde (10)
5-Chloro-3,4-dihydroxybenzaldehyde was prepared according to the procedure of Jong et al. (J. Org. Chem. 1984, 49, 735-6). To a solution of 0.350 g (1.10 mmol) of formyloxy 11 in 20 mL of methanol was added 0.181 g (1.32 mmol) of potassium carbonate. After the solution was stirred at 0°C for 2 h, the solution was diluted with water and extracted three times with diethyl ether. The combined ether extract was washed with brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and ether as eluent to give 0.241 g (92% yield) of aldehyde 10.

Example 3
Preparation of 5-Bromo-6-chloro-1,2,4-tris-(t-butyldimethylsilyloxy)benzene
Step 1: Preparation next of 3-Chloro-4-hydroxy-5-methoxybenzaldehyde (12)
Compound 12 was prepared according to the procedure of Hamm et al. (J. Am. Chem. Soc. 1927, 49, 535-7). To a solution of 2.50 g (16.4 mmol) of vanillin in 15 mL of glacial acetic acid was added chlorine gas through a glass tubing over 30 minutes (with a slow gas flow) at 25°C. White solid product was collected by filtration, washed with 50 mL of hexane, and dried in vacuo to give 2.03 g of 12. As the acetic acid filtrate was again treated with chlorine gas as above for 30 minutes to give another 0.659 g of 12. A total of 2.691 g (88% yield) of 12 was obtained. The white solids were used in next step without purification. 1H NMR (CDCl3) δ 10.04 (s, 1H, OH), 9.76 (s, 1H, CHO), 7.56 (d, J=1.6Hz, 1H, Ar), 7.37 (d, J=1.6Hz, 1H, Ar), 3.91 (s, 3H, OMe); 13C NMR (CDCl3) δ 190.5 (C=O), 149.0 (s, 2C), 128.2 (s), 125.6 (d), 120.1 (s), 109.2 (d), 56.3 (q).

Step 2: Preparation of 5-Chloro-3,4-dihydroxybenzaldehyde
To a solution of 2.00 g (10.7 mmol) of benzaldehyde 12 in 20 mL of dichloromethane under argon at 0°C was added 1.20 mL (11.8 mmol) of boron tribromide. The solution was stirred at 0°C for 0.5 h and 25°C for 4 h, diluted with 40 mL of methanol, and the solvents were removed on a rotary evaporator (the trimethylborate was removed). It was added 40 mL of methanol and methanol and trimethyl borate were removed by evaporation on a rotary evaporator, and this process was repeated three times. The residue was diluted with dichloromethane and filtered and washed with a small amount of dichloromethane to give 1.722 g (94% yield) of pure 5-chloro-3,4-dihydroxybenzaldehyde. This material was used in next step without purification. 1H NMR (CDCl3) δ 10.43 (s, 2H, OH), 9.70 (s, 1H, CHO), 7.42 (d, J=2.0Hz, 1H, C6-H), 7.22 (d, J=2.0Hz, 1H, C2-H); 13C NMR (CDCl3) δ 190.6 (C=O), 148.3 (s), 146.9 (s), 128.4 (d), 124.2 (d), 120.3 (s), 112.5 (s).

Step 3: Preparation of 3,4-bis(t-Butyldimethylsilyloxy)-5-chlorobenzaldehyde (13)
To a solution of 1.68 g (9.70 mmol) of 5-chloro-3,4-dihydroxybenzaldehyde and 0.212 g (2.80 mmol) of 4-dimethylaminoypyridine (DMAP) in 20 mL of dichloromethane under argon at 0°C was added 9.80 mL (68.0 mmol) of distilled triethylamine and 4.40 g (59.2 mmol) of t-butyldimethylsilyl chloride. The reaction mixture was stirred at 0°C for 1 h and 25°C for 3 h. 100 mL of saturated aqueous NH4Cl was added, and extracted three times with
diethyl ether (80 mL each). The combined extracts were washed with 60 mL of brine, dried (MgSO₄), concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluent to give 3.64 g (93% yield). ¹H NMR (CDCl₃) δ 6.97 (s, 1H, CHO), 7.50 (d, J=2.0 Hz, 1H, C6-H), 7.27 (d, J=2.0 Hz, 1H, C2-H), 1.04 (s, 9H, t-Bu), 0.98 (s, 9H, t-Bu), 0.26 (s, 6H, Me), 0.23 (s, 6H, Me); ¹³C NMR (CDCl₃) δ 189.3 (C=O), 149.5 (s), 149.2 (s), 127.8 (s), 125.7 (d), 118.8 (d), 26.1 (q, 3C, t-Bu), 26.0 (q, 3C, t-Bu), 18.7 (s, 2C, t-Bu), -3.4 (q, 2C, Me), -3.6 (q, 2C, Me). Anal. Calcd for C₂₅H₃₂Br₂O₂Si₂: C, 56.90; H, 8.29. Found: C, 56.62; H, 8.41.

Step 4: Preparation of 3,4-bis-(t-Butyldimethylsilyloxy)-5-chlorophenyl Formate

To a solution of 1.73 g (4.30 mmol) of 13 in 15 mL of dichloromethane under argon was added 2.03 g (6.50 mmol) of 55% m-chloroperbenzoic acid (MCPBA). After refluxing for 10 h, the solution was diluted with 30 mL of water and extracted three times with diethyl ether (50 mL each). The combined extracts were washed with saturated aqueous NaHCO₃ (30 mL each), 30 mL of water, and extracted three times with diethyl ether (30 mL each). The combined extracts were washed with brine, dried (MgSO₄), and concentrated to give 1.100 g (83% yield) of 14. ¹H NMR (CDCl₃) δ 8.22 (s, 1H, CHO), 6.79 (d, J=3.2 Hz, 1H), 6.58 (d, J=3.2 Hz, 1H), 1.03 (s, 9H, t-Bu), 0.96 (s, 9H, t-Bu), 0.22 (s, 6H, Me), 0.19 (s, 6H, Me); ¹³C NMR (CDCl₃) δ 159.0 (s, C=O), 148.8 (s), 143.0 (s), 142.4 (s), 127.1 (s), 115.5 (d), 113.1 (d), 26.2 (q, 6C, t-Bu), 18.8 (s, 2C, t-Bu), -3.3 (q, 2C, Me), -3.6 (q, 2C, Me). Anal. Calcd for C₁₉H₂₁Cl₂O₂Si₂: C, 56.90; H, 8.41.

Step 5: Preparation of 1,2,5-tris-(t-Butyldimethylsilyloxy)-3-chlorobenzene (14)

To a mixture of 1.028 g (2.65 mmol) of 3,4-bis-(t-butyldimethylsilyloxy)-5-chlorophenol, 0.600 g (4.00 mmol) of t-butyldimethylsilyl chloride, and 0.048 g (0.40 mmol) of 4-dimethylaminopyridine in 10 mL of dichloromethane under argon at 25°C was added 1.30 mL (9.26 mmol) of triethylamine. After stirring at 25°C for 10 h, the mixture was diluted with 30 mL of water and extracted three times with diethyl ether (50 mL each). The combined extracts were washed with 30 mL of brine, dried (MgSO₄), concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as eluent to give 1.24 g (70% yield) of 3,4-bis-(t-butyldimethylsilyloxy)-5-chlorophenyl formate. ¹H NMR (CDCl₃) δ 8.22 (s, 1H, CHO), 6.79 (d, J=3.2 Hz, 1H), 6.58 (d, J=3.2 Hz, 1H), 1.03 (s, 9H, t-Bu), 0.96 (s, 9H, t-Bu), 0.22 (s, 6H, Me), 0.19 (s, 6H, Me); ¹³C NMR (CDCl₃) δ 159.0 (s, C=O), 148.8 (s), 143.0 (s), 142.4 (s), 127.1 (s), 115.5 (d), 113.1 (d), 26.2 (q, 6C, t-Bu), 18.8 (s, 2C, t-Bu), -3.3 (q, 2C, Me), -3.6 (q, 2C, Me). Anal. Calcd for C₂₀H₂₄Cl₂O₂Si₂: C, 57.27; H, 9.55. Found: C, 57.37; H, 9.55.

Example 4

5-Bromo-6-chloro-1,2,4-tris-(t-butyldimethylsilyloxy)benzene (16)

Step 1: Preparation of 3,4-bis-(t-Butyldimethylsilyloxy)-5-chlorophenol (16)

To a solution of 1.236 g (2.97 mmol) of 3,4-bis-(t-butyldimethylsilyloxy)-5-chlorophenyl formate in 10 mL of methanol was added 2.05 g (15.0 mmol) of potassium carbonate at 25°C. The solution was stirred for 30 min., diluted with 35 mL of water, and extracted three times with diethyl ether (50 mL each). The combined extracts were washed with brine, dried (MgSO₄), and concentrated to give 1.028 g (90% yield) of 3,4-bis-(t-butyldimethylsilyloxy)-5-chlorophenol. ¹H NMR (CDCl₃) δ 6.45 (d, J=2.8 Hz, 1H), 6.31 (d, J=2.8 Hz, 1H), 1.00 (s, 9H, t-Bu), 0.93 (s, 9H, t-Bu), 0.18 (s, 6H, Me), 0.15 (s, 6H, Me); ¹³C NMR (CDCl₃) δ 149.7 (s), 148.9 (s), 137.7 (s), 126.9 (s), 109.8 (d), 107.8 (d), 26.3 (q, 3C), 26.2 (q, 3C), -3.6 (q, 2C, Me), -3.4 (q, 2C, Me). Anal. Calcd for C₁₉H₁₄BrCl₂O₂Si₂: C, 55.57; H, 8.55. Found: C, 55.39; H, 8.87.

Step 2: Preparation of 2-Bromo-3-chloro-4,5-bis-(t-butyldimethylsilyloxy)phenol (17)

A solution of 0.050 g (0.12 mmol) of 16 and 0.023 g (0.12 mmol) of NBS in 2 mL of DMF under argon was stirred at 25°C for 1 day. The reaction mixture was diluted with 30 mL of water, extracted three times with diethyl ether (40 mL each), and the combined extracts were washed with brine (30 mL), dried (MgSO₄), and concentrated to give 0.042 g (70% yield). This material was used in next step without purification. ¹H NMR (CDCl₃) δ 6.53 (s, 1H, Ar), 6.03 (s, 9H, t-Bu), 0.96 (s, 9H, t-Bu), 0.22 (s, 6H, Me), 0.17 (s, 6H, Me); ¹³C NMR (CDCl₃) δ 149.3 (s), 147.4 (s), 138.8 (s), 127.0 (s), 106.9 (d), 102.9 (s), 26.2 (q, t-Bu), 18.8 (s), -3.3 (q, Me), -3.5 (q, Me). Anal. Calcd for C₁₉H₁₄BrCl₂O₂Si₂: C, 55.57; H, 8.55. Found: C, 55.39; H, 8.87.

Step 3: Preparation of 5-Bromo-6-chloro-1,2,4-tris-(t-butyldimethylsilyloxy)benzene

To a mixture of 0.042 g (0.090 mmol) of 17, 0.016 g (0.06 mmol) of DMAP in 2 mL of dichloromethane under argon was added 2.05 g (15.0 mmol) of potassium carbonate at 25°C. The solution was stirred for 30 min., diluted with 35 mL of water, and extracted three times with diethyl ether (50 mL each). The combined extracts were washed with brine, dried (MgSO₄), and concentrated to give 0.051 g (99% yield) of 4.
2-Bromo-5-chloro-1,3,4-tris-(t-butyldimethylsilyloxy)benzene

A solution of 0.100 g (0.20 mmol) of 14 and 0.0354 g (0.20 mmol) of NBS in 2 mL of DMF under argon was stirred at 50°C for 2 day. The solution was diluted with 30 mL of water, extracted three times with diethyl ether (30 mL each), and the combined extracts were washed with brine, dried (MgSO₄), concentrated, and column chromatographed on silica gel using a mixture of hexane and diethyl ether as eluent to give 0.980 g (45% yield) of 15, Compound 15: 'H NMR (CDCl₃) δ 2.07 (3H, Me), 0.97 (3H, Me), 0.95 (3H, t-Bu), 0.92 (3H, t-Bu), 0.20 (3H, t-Bu), 0.18 (3H, Me). I3C NMR (CDCl₃) δ 151.9, 147.5, 146.0, 138.0, 123.6, 115.7, 117.1, 107.9, 78.0, 52.4, 41.8, 37.9, 38.6, 33.8, 33.6, 26.4 (3C, t-Bu). 23.1, 21.7, 21.9, 19.5, 19.1, 18.9, -3.2, -3.46, -3.39, -3.6. Compound 19: [c]D²₂ ≡ +56° (c 0.018, CHCl₃); 'H NMR (CDCl₃) δ 6.39 (1H, C₈-H), 6.28 (1H, C₁₂-H), 2.20-0.90 (m, 11H), 1.31 (3H, Me), 1.23 (3H, Me), 1.03 (3H, Me), 0.96 (9H, t-Bu), 0.95 (3H, Me), 0.86 (3H, Me), 0.21 (3H, Me), 0.15 (3H, Me). ¹³C NMR (CDCl₃) δ 151.9, 147.5, 146.0, 138.0, 123.8, 116.5, 111.9, 108.0, 78.0, 52.2, 44.1, 39.4, 39.1, 34.0, 33.0, 31.1, 26.4 (3C, t-Bu), 26.3 (3C, t-Bu), 25.5, 25.1, 23.7, 21.4, 19.2, 18.9, 18.8, 17.6, -3.3, -3.4, -3.5, -3.6. Anal. Calc. for C₃₃H₆₅ClO₃Siz: c, 67.02; H, 9.37. Found: c, 67.11; H, 9.16.

2D NOESY spectra were obtained and in compound 18, C₆a methyl and C₁₂b methyl have NOE connectivity, however, in compound 19, C₆a methyl and C₁₂b methyl have no NOE connectivity.

Step 2: Preparation of (4aS,6aR,12bS)-2H-11-Chloro-1,3,4,4a,5,6,6a,12b-octahydro-4,4,6a,12b-tetramethyl-benzo[a]xanthene-9,10-diol (1)

To a solution of 0.160 g (0.270 mmol) of 18 in 3 mL of THF under argon at 25°C was added 0.58 mL (0.600 mmol) of tetra-n-butylammonium fluoride (1.0 M in THF). After stirring at 25°C for 5 min, 0.30 mL of acetic acid was added, the resulting solution was concentrated on a rotary evaporator, and column chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as eluent to give 0.080 g (82% yield) of 1. [α]D²₂ ≡ +50° (c 0.018, CHCl₃); 'H NMR (CDCl₃) δ 6.42-6.20 (broad s, 1H, C₈-H), 6.18 (d, J=12 Hz, 1H), 2.01 (d, J=12 Hz, 1H), 1.86-0.90 (a series of m, 9H), 1.37 (3H, Me). 13C NMR (CDCl₃) δ 151.3, 147.3, 146.1, 138.1, 123.6, 115.7, 111.7, 107.9, 78.0, 42.3, 41.8, 38.2, 34.0, 33.9, 33.5, 33.0, 21.9, 21.4, 20.9, 19.5, 19.1.

To a solution of 60 mg (0.10 mmol) of 19 in 2 mL of THF under argon at 25°C was added 0.22 mL (0.22 mmol) of...
tetra-n-butylammonium fluoride (1 M in THF). After stirring at 25°C for 10 min., 0.10 mL of acetic acid was added, the solution was concentrated on a rotary evaporator, and the residue was column chromatographed on silica gel using a gradient mixture of hexane and ethyl acetate as eluent to give 30 mg (81.4% yield) of 2, [α]D=+1,1~. Step 2: Preparation of using a gradient mixture of hexane and ethyl acetate as

0.194 MeSi), 0.15 (s, 3H, Me); 13C NMR (CDCl3) δ 151.3, 148.5, 146.1, 133.6, 123.6, 116.5, 110.6, 103.0, 78.0, 43.8, 42.0, 39.1, 33.8, 32.7, 30.8, 30.3, 25.0, 21.2, 20.5, 18.9, 17.2.

Example 8

(4aS,6aR,12aR,12bS)-2H-11-Chloro-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-4,4,6a,12b-tetramethyl-benz[a]xanthene-9,10-dione (23) and

(4aS,6aR,12aR,12bS)-2H-11-Chloro-1,3,4,4a,5,6a,9,10,12,12a-decahydro-4,4,6a,12b-tetramethyl-benz[a]xanthene-9,10-dione (24)

A mixture of 0.180 g (0.300 mmol) of compound 18 and 0.060 g of 10% palladium/carbon in 2 mL of distilled dichloromethane, filtered through Celite, and concentrated to dryness to give 9.0 mg of a mixture of 23 and 24 in a ratio of 9:1 (obtained from NMR spectrum). 'H NMR (CDCl3) δ 6.35 (s, 1H, C8H), 5.06 (broad s, 1H, OH), 2.61 (d, J=17 Hz, 1H, C12H), 2.34 (m, 1H, C12H), 2.02 (dt, J=13, 3 Hz, 1H), 1.80-1.5 (a series of m, 11H), 1.14 (s, 3H, Me), 0.91 (s, 3H, Me), 0.85 (s, 3H, Me); when the proton NMR spectrum was measured in benzene-d6 solvent, all methyl groups are separated, δ 0.99 (s, 3H, Me), 0.77 (s, 3H, Me), 0.37 (s, 3H, Me), 0.31 (s, 3H, Me). 13C NMR (CDCl3) δ 147.4, 147.1, 146.6, 146.1, 139.5, 133.6, 133.4, 131.0, 129.2, 128.7, 128.1, 127.6, 125.8, 125.5, 124.6, 124.2, 123.6, 121.5, 119.7, 118.1, 117.8, 117.5, 117.4, 117.2, 116.8, 116.4, 116.3, 115.9, 115.8, 115.6, 115.5, 115.3, 115.0-3.2 (MeSi), -3.4, -3.5 (2C).

Example 9

(+) Chloropuupehenone

A mixture of 0.060 g (0.10 mmol) of compound 19 and 0.080 g of 10% palladium/carbon in 2 mL of distilled...
ethanol was charged with 1 atmosphere of hydrogen gas (by the use of a hydrogen balloon), and the mixture was stirred at 25°C for 2 h. The reaction mixture was filtered through Celite, washed with dichloromethane, and the combined filtrate was concentrated, and column chromatographed on silica gel using a gradient mixture of hexane and toluene as eluent to give 0.54 g (90% yield) of compound 25. [α]D20 = −35° (c 0.007, CHCl3). 1H NMR (CDCl3) δ 6.12 (s, 1H, C8H), 5.84 (d, J=7 Hz, 1H, C12H), 2.10 (d, J=11 Hz, 1H), 1.85 (d, J=12 Hz, 1H), 1.62–1.10 (a series of m, 10H), 1.11 (s, 3H, Me), 1.03 (s, 9H, t-Bu), 0.95 (s, 9H, t-Bu), 0.89 (s, 3H, Me), 0.81 (s, 3H, Me), 0.64 (s, 3H, Me), 0.20 (s, 3H, MeSi), 0.18 (s, 3H, MeSi), 0.16 (s, 3H, MeSi), 0.157 (s, 3H, MeSi). 13C NMR (CDCl3) δ 148.9, 146.3, 137.3, 126.0, 114.6, 108.4, 75.4, 55.9, 49.7, 42.1, 40.7, 40.3, 38.6, 33.9, 33.5, 27.1, 26.4 (3C, t-Bu), 26.3 (3C, t-Bu), 22.1, 21.9, 18.9, 18.7, 18.5, 14.1, −3.3 (2C, MeSi), −3.5, −3.6. Anal. Calcd for C40H52ClO4Si8: C, 71.49; H, 4.86. Found: C, 71.24; H, 5.00.

Step 2: Preparation of (−)-Chloropuupehenone (27)

To a solution of 6.0 mg (0.016 mmol) of 26 in 1 mL of THF under argon at 25°C, C12H, 5.84 (d, J=7 Hz, 1H, C12H), 2.10 (d, J=11 Hz, 1H), 1.85 (d, J=12 Hz, 1H), 1.62–1.10 (a series of m, 10H), 1.11 (s, 3H, Me), 1.03 (s, 9H, t-Bu), 0.95 (s, 9H, t-Bu), 0.89 (s, 3H, Me), 0.81 (s, 3H, Me), 0.64 (s, 3H, Me), 0.20 (s, 3H, MeSi), 0.18 (s, 3H, MeSi), 0.16 (s, 3H, MeSi), 0.157 (s, 3H, MeSi). 13C NMR (CDCl3) δ 148.9, 146.3, 137.3, 126.0, 114.6, 108.4, 75.4, 55.9, 49.7, 42.1, 40.7, 40.3, 38.6, 33.9, 33.5, 27.1, 26.4 (3C, t-Bu), 26.3 (3C, t-Bu), 22.1, 21.9, 18.9, 18.7, 18.5, 14.1, −3.3 (2C, MeSi), −3.5, −3.6. Anal. Calcd for C40H52ClO4Si8: C, 71.49; H, 4.86. Found: C, 71.24; H, 5.00.

Step 3: Preparation of (+)-Chloropuupehenone (27)

To a solution of 50 mg (0.084 mmol) of 25 in 2 mL of THF under argon at 25°C, C12H, 5.84 (d, J=7 Hz, 1H, C12H), 2.10 (d, J=11 Hz, 1H), 1.85 (d, J=12 Hz, 1H), 1.62–1.10 (a series of m, 10H), 1.11 (s, 3H, Me), 1.03 (s, 9H, t-Bu), 0.95 (s, 9H, t-Bu), 0.89 (s, 3H, Me), 0.81 (s, 3H, Me), 0.67 (s, 3H, Me). 13C NMR (CDCl3) δ 149.1, 141.3, 133.3, 119.1, 112.4, 103.3, 75.7, 68.2, 55.4, 49.4, 42.1, 40.6, 40.3, 38.5, 33.9, 33.4, 27.1, 18.7, 18.4, 14.3.

Example 10

**Lympthic Absorption of Cholesterol**

Ten male Sprague-Dawley rats (Harlan Sprague Dawley, Inc., Indianapolis, Ind.) weighing 274.3±7.8 grams were housed individually in plastic cages in an environmentally controlled room of illumination (12:12-h light/dark cycle with the dark period from 0330 to 1530), humidity (60–70%), and temperature (22–25°C) throughout the study. Rats had free access to deionized water and a nutritionally adequate diet (Table 1) containing soybean oil as the fat source and egg white as the protein source. The diet was formulated according to AIN-93G recommendations (In: Trace Elements in Laboratory Rodents (Watson, R. R., ed.), pp. 3–37. CRC Press, Boca Raton, Fla.). Animals were cared for in an animal care facility accredited by the American Association for the Accreditation of Laboratory Animal Care. Rats were maintained in accordance with the policies and guidelines for animal care and use procedures of the Kansas State University Institutional Animal Care and Use Committee.

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Amount (g/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egg white</td>
<td>200.0</td>
</tr>
<tr>
<td>Cornstarch</td>
<td>396.5</td>
</tr>
<tr>
<td>Dextrinized cornstarch</td>
<td>132.0</td>
</tr>
<tr>
<td>Dextrose</td>
<td>100.0</td>
</tr>
<tr>
<td>Cellulose</td>
<td>50.0</td>
</tr>
<tr>
<td>Soybean oil²</td>
<td>70.0</td>
</tr>
<tr>
<td>Mineral mix</td>
<td>35.0</td>
</tr>
<tr>
<td>Vitamin mix</td>
<td>10.0</td>
</tr>
<tr>
<td>Biotin (1 mg/g biotin sucrose mix)</td>
<td>4.0</td>
</tr>
<tr>
<td>Choline bitarate</td>
<td>2.5</td>
</tr>
</tbody>
</table>

At 6 wk, rats were starved overnight for 17 h but allowed water ad libitum prior to the surgical placement of a lymph cannula and duodenal infusion catheter. The mesenteric lymph duct was cannulated as described in Koo et al., J. Nutr. 131: 717–722 (2001). Briefly, while rats were under anesthesia (2.0% halothane in 2.0 L O2/min delivered via a halothane vaporizer), a midline abdominal incision was made. The superior mesenteric lymph duct was cannulated with polyethylene tubing (SV 3.1 tubing, i.d. 0.5 mm, o.d. 0.80 mm; Dow Corning, Midland, Mich.) was introduced via the gastric fundus into the upper duodenum and secured in place with a purse-string suture (4-0 Silk, Ethicon, Somerville, N.J.) around the fundic incision. The infusion catheter was exteriorized, along with the lymph cannula. After the abdominal incision was closed, the rats were placed in restraining cages and housed in a recovery chamber at 30°C for postoperative recovery for 22–24 h. During the recovery period, rats were infused continuously with glucose in phosphate buffered saline (PBS) (in mmol/L: 277 glucose, 6.75 NaH2PO4, 16.5 Na2HPO4, 115 NaCl, and 5 KCl; pH 6.7) via infusion catheter at 3.0 mL/h by a syringe pump (Harvard Apparatus, Model 935, South Natick, Mass.) to ensure adequate hydration and nutritional status of the animals.

After postoperative recovery, each rat was infused with a lipid emulsion at 3 mL/h for 8 h via the duodenal catheter in subdived light. The lipid emulsion consisted of 451.8 μmol triolein (95%, Sigma Chemical, St. Louis, Mo.), 33.3 kBq [14C]-cholesterol (14C-CH₂; specific activity, 1.85 GBq/mmol, American Radiolabeled Chemicals, St. Louis, Mo.), and 33.3 kBq [3H]-cholesterol (3H-CH₂; specific activity, 9.2 GBq/mmol, American Radiolabeled Chemicals, St. Louis, Mo.).
20.7 μmol cholesterol, 3.1 μmol α-tocopherol (all-rac-dl-α-tocopherol, 97%, Aldrich Chemical, Milwaukee, Wis.) as an antioxidant, and 396.0 μmol sodium taurocholate (Sigma Chemical, St. Louis, Mo.) in 24 mL of PBS buffer, pH 6.5. For half of the rats, the lipid emulsion contained 114.9 μmol compound 1 (41.9 mg). Lipid emulsion was prepared under a gentle N2 stream and subdued light for 55 min using a microprocessor-controlled ultrasonicator equipped with a microtip (XL-2020 Ultrasonic Liquid Processor, Misonix, Farmingdale, N.Y.).

During the duodenal infusion of lipid emulsion, lymph samples were collected hourly in preweighed ice-chilled centrifuge tubes containing 4 mg Na2-EDTA and 30 μg n-propyl gallate (Sigma Chemical, St. Louis, Mo.) as antioxidants. A portion of each lymph sample (100 μL) was mixed with scintillation liquid (ScintiVerse; Fisher Scientific, Fair Lawn, N.J.) and counted by scintillation spectrometry (Beckman LS-6500; Beckman Instruments, Fullerton, Calif.). The total 14C-radioactivity appearing in hourly lymph volume (the hourly rates of 14C-CH absorption) was expressed as a percentage of the total radioactivity infused (% dose). All samples were ice chilled and handled in subdued light.

Fatty Acid Analysis

Total lipids were extracted from each lymph sample with a chloroform/methanol mixture. Lipid extracts were then hydrolyzed with methanolic NaOH, and fatty acids were saponified and methylelated simultaneously with BF3-methanol. Fatty acid methyl esters (FAME) were analyzed by capillary gas chromatography (Hewlett-Packard, Model 6890, Palo Alto, Calif.) using a HP-INNOWax cross-linked polyethylene glycol phase capillary column (15 m, i.d. 0.53 mm; Restek Corp., Bellefonte, Pa.).

Statistical analysis

All statistical analyses were performed using PC SAS (SAS Institute, Cary, N.C.). Repeated measures ANOVA and the least significance difference that were used to compare group means. The level of significance was determined at P<0.05.

Results

Table 2 shows the lymphatic absorption of 14C-cholesterol and triolein, as well as lymph flow in rats infused for eight hours with lipid emulsion only (control) or containing compound 1. The lymph volume was not significantly different between the two treatments. However, total cholesterol absorption was significantly less in rats infused with compound 1, compared to control rats. In addition, absorption of triolein was significantly less in rats infused with compound 1 compared to control rats. Table 3 and FIG. 1 show the percent dose of 14C-cholesterol absorbed at hourly intervals. FIG. 2 shows the amount of oleic acid absorbed in the lymph at hourly intervals.

<table>
<thead>
<tr>
<th>TABLE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymp lipid</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Lymp volume, mL/h</td>
</tr>
<tr>
<td>14C-CH, % dose/h</td>
</tr>
<tr>
<td>Oleic acid, μmol/h</td>
</tr>
</tbody>
</table>

4Means ± SD, n = 5. *Significantly different from control rats (P < 0.05).

After 8 hours of treatment, the control rats (without drug) had a percent cholesterol absorption of 37.69%, while the treated rats (treated with compound 1) had a percent cholesterol absorption of 10.95%. Under similar test conditions, rats infused with 120.5 mg of green tea catechins per rat per 8 hours had a percent cholesterol absorption of about 10%.

Thus, compound 1 is a more potent inhibitor than green tea catechins, since an inhibitory effect was observed with only 41.9 mg of compound 1. Rats exhibited no gross motor or behavioral abnormalities.

Rats were sacrificed at the day end of the infusion, and the intestine and other organs were dissected and visually examined. No abnormalities were found in any of the organs of either control or treated rats.

<table>
<thead>
<tr>
<th>TABLE 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>1 h</td>
</tr>
<tr>
<td>3 h</td>
</tr>
<tr>
<td>4 h</td>
</tr>
<tr>
<td>5 h</td>
</tr>
<tr>
<td>6 h</td>
</tr>
<tr>
<td>7 h</td>
</tr>
<tr>
<td>8 h</td>
</tr>
<tr>
<td>9 h</td>
</tr>
</tbody>
</table>

*Values are means ± SD and cumulative at hourly intervals, n = 5. *Significantly different from control rats (P < 0.05).

Example 11

The inhibitory effect of compound 1 on the activity of cholesterol ester transfer protein (CETP) was measured, using a crude CETP preparation derived from hamster plasma. The results suggested that when the dose of compound 1 exceeded 250 μM, there was an increase in HDL total cholesterol, HDL free cholesterol, and HDL cholesterol ester. These increased HDL levels suggest that compound 1 is an inhibitor of CETP activity in vitro.

The effect of compound 24 on inhibition of CETP was tested using a purified CETP preparation. CETP was purified and assayed according to procedures described in Tomoda, H.; Tabata, N.; Shinose, M.; Takahashi Y.; Woodruff, H. B.; Omura, S. J. Antibiotics, 52: 1101-1107 (1999). As shown in FIG. 3, there was 50% inhibition (IC50) of CETP activity at 31 μM of compound 24. In comparison, Ferroverdin A, a known CETP inhibitor, resulted in an IC50 of about 22 μM (FIG. 4). The data for compound 24 suggest that compound 24 can inhibit CETP activity in vitro.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

What is claimed is:

I. A compound of Formula I:

wherein R1 is independently hydroxydial, halo, alky, alkenyl, alky1, haloalkyl, hydroxyalkyl, hydroxy, alkoxyl,
alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfonamyl, N-alkyl-N-arylsulfonamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxy carbonyl, alkoxy carbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamido, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, arylsulfonyl, amido, amino, cyano, amino, nitro, sulfonate, alkylysilyl, phenylselenenyl, thiol, arylsulfenyl, alkylsilyloxy, or alkylsilyloxy; 

R₁ is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfonamyl, N-alkyl-N-arylsulfonamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxy carbonylalkyl, alkoxycarbonylalkyl, amido, N,N-dialkylamido, N-alkyl-N-dialkylamido, N-aryl-N-dialkylamido, N,N-dialkylsulfamyl, N,N-dialkylsulfonamyl, alkylsulfonyl, N,N-dialkylsulfonyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamido, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N,N-dialkylamino, acyl, acyloxy, arylsulfonyl, ammonium, amino, cyano, nitro, sulfonate, alkylysilyl, or phenylselenenyl, thiol, arylsulfenyl, alkylsilyloxy, or alkylsilyloxy; 

R₂ is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfonamyl, N-alkyl-N-arylsulfonamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N,N-dialkylamido, N-alkyl-N-dialkylamido, N-aryl-N-dialkylamido, N,N-dialkylsulfamyl, N,N-dialkylsulfonamyl, alkylsulfonyl, N,N-dialkylsulfonyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamido, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N,N-dialkylamino, acyl, acyloxy, arylsulfonyl, ammonium, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsilyloxy, or alkylsilyloxy; 

R₃ is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfonamyl, N-alkyl-N-arylsulfonamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxy carbonylalkyl, alkoxycarbonylalkyl, amido, N,N-dialkylamido, N-alkyl-N-dialkylamido, N-aryl-N-dialkylamido, N,N-dialkylsulfamyl, N,N-dialkylsulfonamyl, alkylsulfonyl, N,N-dialkylsulfonyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamido, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N,N-dialkylamino, acyl, acyloxy, arylsulfonyl, ammonium, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsilyloxy, or alkylsilyloxy; 

R₁ and R₂ are independently hydrido, alkyl, or hydroxyalkyl; 

or a pharmaceutically-acceptable salt thereof.

2. The compound of claim 1, wherein R₁ is halo, R₂ and R₃ are hydroxy, and R₁ and R₂ are alkyl.

3. The compound of claim 2, wherein R₁ is chloro and R₃ and R₂ are methyl.

4. The compound of claim 1, wherein R₁ is halo, R₂ and R₃ are alkylsilyloxy, and R₁ and R₂ are alkyl.

5. The compound of claim 4, wherein R₁ is chloro, R₂ and R₃ are OSi-t-BuMe₂, and R₁ and R₂ are methyl.

6. The compound of claim 1, wherein said compound has Formula (24): 

\[
C_1 \quad O
\]

7. A compound of Formula II: 

wherein R₁ is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfonamyl, N-alkyl-N-arylsulfonamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N,N-dialkylamido, N-alkyl-N-dialkylamido, N-aryl-N-dialkylamido, N,N-dialkylsulfamyl, N,N-dialkylsulfonamyl, alkylsulfonyl, N,N-dialkylsulfonyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamido, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N,N-dialkylamino, acyl, acyloxy, arylsulfonyl, ammonium, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsilyloxy, or alkylsilyloxy; 

R₂ is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfonamyl, N-alkyl-N-arylsulfonamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N,N-dialkylamido, N-alkyl-N-dialkylamido, N-aryl-N-dialkylamido, N,N-dialkylsulfamyl, N,N-dialkylsulfonamyl, alkylsulfonyl, N,N-dialkylsulfonyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamido, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N,N-dialkylamino, acyl, acyloxy, arylsulfonyl, ammonium, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsilyloxy, or alkylsilyloxy.

Formula (24): 

\[
O \quad II 
\]
R, are alkylsilyloxy; and R, and R, are alkyl.

R, are hydroxy, and R, and R, are alkyl.

and R, are OS-t-BuMe,, and R, and R, are methyl.

wherein R, is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylalkylsulfamyl, carboxy, carboxyalkyl, alkylcarboxyl, alkylcarboxylalkyl, alkoxycarboxyl, alkoxycarboxylalkyl, amido, N-alkylamido, N,N-dialkylamido, N-arylalkylamido, N-aryl-N-hydroxyamido, N-aryl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amido, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkythio, alkysulfinyl, N-alkylamido, N,N-dialkylamido, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfonyl, alkylsulfonyl, phenylselenyl, or alkylsilyloxy;

R, is independently hydrido, halo, alkyl, or hydroxyalkyl; or

R, is independently hydrido, alkyl, or hydroxyalkyl; or a pharmaceutically-acceptable salt thereof, wherein when R, is chloro, R, and R, are not hydroxy and R, and R, are methyl.

8. The compound of claim 7, wherein R, is halo, R, and R, are hydroxy, and R, and R, are alkyl.

9. The compound of claim 7, wherein R, is halo, R, and R, are alkylsilyloxy; and R, and R, are alkyl.

10. The compound of claim 9, wherein R, is chloro, R, and R, are OSi-t-BuMe,, and R, and R, are methyl.

11. A compound of Formula III:

wherein R, is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylalkylsulfamyl, carboxy, carboxyalkyl, alkylcarboxyl, alkylcarboxylalkyl, alkoxycarboxyl, alkoxycarboxylalkyl, amido, N-alkylamido, N,N-dialkylamido, N-arylalkylamido, N-aryl-N-hydroxyamido, N-aryl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amido, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkythio, alkysulfinyl, N-alkylamido, N,N-dialkylamido, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfonyl, alkylsulfonyl, phenylselenyl, or alkylsilyloxy;

R, is independently hydrido, halo, alkyl, alkenyl, alkyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylalkylsulfamyl, carboxy, carboxyalkyl, alkylcarboxyl, alkylcarboxylalkyl, alkoxycarboxyl, alkoxycarboxylalkyl, amido, N-alkylamido, N,N-dialkylamido, N-arylalkylamido, N-aryl-N-hydroxyamido, N-aryl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amido, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkythio, alkysulfinyl, N-alkylamido, N,N-dialkylamido, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfonyl, alkylsulfonyl, phenylselenyl, or alkylsilyloxy.
17. A compound of Formula IV:

wherein \( R_1 \) is independently hydrido, halo, alkylenyl, alkyly, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonfyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, carboxy, carboxyalkyl, alkylicarbonyl, alkylicarboxyalkyl, alkoxycarbonyl, alkoxycarbonylethyl, cycloalkyl, cycloalkenyl, N-alloylamido, N,N-dialkylamido, N-monoarylamido, N-aryl-N-arylamido, N-alkyl-N-aryl-N-arylamido, N-alkyl-N-hydroxyamidoalkyl, N,N-dialkylaminocarbonyl, N-alkyl-N-alkylaminocarbonyl, amidido, amidicarbonylethyl, alkylsilyloxy; and \( R_2 \) is selected from hydroxy, alkoxycarbonyl, arylsulfonyl, or a pharmaceutically-acceptable salt thereof.

18. The compound of claim 17, wherein \( R_1 \) is halo; \( R_2 \) and \( R_3 \) are selected from hydroxy, alkoxycarbonyl, or aralkylamido; \( R_4 \) and \( R_5 \) are alkyl; \( R_6 \) is selected from hydroxy, acyloxy, or acylamino; and \( R_7 \) is independently alkyl, or arylselenylalkyl; or a pharmaceutically-acceptable salt thereof.

19. The compound of claim 18, wherein \( R_1 \) is chloro; \( R_2 \) and \( R_3 \) are OSi-t-BuMe; \( R_4 \) and \( R_5 \) are methyl; \( R_6 \) is hydrido; and \( R_7 \) is methyl.

20. The compound of claim 18, wherein \( R_1 \) is chloro; \( R_2 \) and \( R_3 \) are acyloxy; \( R_4 \) and \( R_5 \) are methyl; \( R_6 \) is acyloxy; and \( R_7 \) is arylselenylalkyl.

21. The compound of claim 18, wherein \( R_1 \) is chloro; \( R_2 \) and \( R_3 \) are aryalkylamido; \( R_4 \) and \( R_5 \) are methyl; \( R_6 \) is hydroxy; and \( R_7 \) is arylselenylalkyl.

22. The compound of claim 18, wherein \( R_1 \) is chloro; \( R_2 \) and \( R_3 \) are aryalkylamido; \( R_4 \) and \( R_5 \) are methyl; \( R_6 \) is acyloxy; and \( R_7 \) is arylselenylalkyl.

23. The compound of claim 18, wherein \( R_1 \) is chloro; \( R_2 \) and \( R_3 \) are aryalkylamido; \( R_4 \) and \( R_5 \) are methyl; \( R_6 \) is acyloxy; and \( R_7 \) is methyl.

24. A compound of Formula V:

wherein \( R_1 \) is independently hydrido, halo, alkylenyl, alkyly, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonfyl, arylsulfonyl, N-alkylsulfamyl, N,N-diaklylsulfamyl, carboxy, carboxyalkyl, alkylicarbonyl, alkylicarboxyalkyl, alkoxycarbonyl, alkoxycarbonylethyl, cycloalkyl, cycloalkenyl, N-alloylamido, N,N-dialkylamido, N-monoarylamido, N-aryl-N-arylamido, N-alkyl-N-aryl-N-arylamido, N-alkyl-N-hydroxyamidoalkyl, N,N-dialkylaminocarbonyl, N-alkyl-N-alkylaminocarbonyl, amidido, amidicarbonylethyl, alkylsilyloxy; and \( R_2 \) is selected from hydroxy, alkoxycarbonyl, arylsulfonyl, or a pharmaceutically-acceptable salt thereof.

25. A compound of Formula V:

wherein \( R_1 \) is independently hydrido, halo, alkylenyl, alkyly, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonfyl, arylsulfonyl, N-alkylsulfamyl, N,N-diaklylsulfamyl, carboxy, carboxyalkyl, alkylicarbonyl, alkylicarboxyalkyl, alkoxycarbonyl, alkoxycarbonylethyl, cycloalkyl, cycloalkenyl, N-alloylamido, N,N-dialkylamido, N-monoarylamido, N-aryl-N-arylamido, N-alkyl-N-aryl-N-arylamido, N-alkyl-N-hydroxyamidoalkyl, N,N-dialkylaminocarbonyl, N-alkyl-N-alkylaminocarbonyl, amidido, amidicarbonylethyl, alkylsilyloxy; and \( R_2 \) is independently hydrido, halo, alkylenyl, alkyly, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonfyl, arylsulfonyl, N-alkylsulfamyl, N,N-diaklylsulfamyl, carboxy, carboxyalkyl, alkylicarbonyl, alkylicarboxyalkyl, alkoxycarbonyl, alkoxycarbonylethyl, cycloalkyl, cycloalkenyl, N-alloylamido, N,N-dialkylamido, N-monoarylamido, N-aryl-N-arylamido, N-alkyl-N-aryl-N-arylamido, N-alkyl-N-hydroxyamidoalkyl, N,N-dialkylaminocarbonyl, N-alkyl-N-alkylaminocarbonyl, amidido, amidicarbonylethyl, alkylsilyloxy; and \( R_3 \) is independently hydrido, halo, alkylenyl, alkyly, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonfyl, arylsulfonyl, N-alkylsulfamyl, N,N-diaklylsulfamyl, carboxy, carboxyalkyl, alkylicarbonyl, alkylicarboxyalkyl, alkoxycarbonyl, alkoxycarbonylethyl, cycloalkyl, cycloalkenyl, N-alloylamido, N,N-dialkylamido, N-monoarylamido, N-aryl-N-arylamido, N-alkyl-N-aryl-N-arylamido, N-alkyl-N-hydroxyamidoalkyl, N,N-dialkylaminocarbonyl, N-alkyl-N-alkylaminocarbonyl, amidido, amidicarbonylethyl, alkylsilyloxy; and \( R_4 \) is independently alkyl, or arylselenylalkyl; or a pharmaceutically-acceptable salt thereof.
amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfamate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylethyl, or alkysilyloxy;  
R₃ is independently hydrido, halo, alkyl, alkenyl, alkylid, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfonamyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkyloxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N,N-dialkylamido, N-monooamidido, N-alkyl-N-arylamidido, N-alkyl-N-hydroxyamidido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylethyl, or alkysilyloxy;  
R₁ is independently hydrido, halo, or hydroxyalkyl;  
R₂ is independently hydrido, alkyl, or hydroxyalkyl;  
R₃ is hydroxy; and  
R₄ is independently hydroxy, or alkysilyloxy; or a pharmaceutically-acceptable salt thereof.

25. The compound of claim 24, wherein R₁ is halo, R₂ and R₃ are aralkyloxy; R₄ and R₅ are alkyl; R₆ is hydroxy; and R₇ is selected from hydroxy and alkysilyloxy.

26. The compound of claim 25, wherein R₁ is chloro; R₂ and R₃ are OBn; and R₄ and R₅ are methyl; R₆ is hydroxy; and R₇ is OSI-t-BuMe₂.

27. The compound of claim 25, wherein R₁ is chloro; R₂ and R₃ are OBn; R₄ and R₅ are methyl; R₆ is hydroxy; and R₇ is hydroxy.

28. A method of synthesizing a compound of Formula I:

(1)

wherein R₁ is chloro, R₂ and R₃ are hydroxy; and R₄ and R₅ are methyl, comprising:

a) reacting compound (4),

b) disilylating compound (25) to form compound (26); and

c) deprotecting said intermediate compound.
A composition comprising a compound of Formula 1:

\[
\text{Formula 1}
\]

at least one pharmaceutically-acceptable carrier material.

c) oxidizing compound (26) to form (+) chloropuupehenone (27).

30. A method for identifying a compound that inhibits lymphatic absorption of cholesterol, comprising:
a) administering a known amount of cholesterol and a compound of claim 1 to a non-human mammal; and
b) measuring lymphatic absorption of said known amount of cholesterol, wherein a statistically significant decrease in said cholesterol absorption relative to the lymphatic cholesterol absorption of a corresponding control non-human mammal indicates said compound inhibits lymphatic absorption of cholesterol, and wherein a statistically insignificant change or a statistically significant increase in said cholesterol absorption relative to the lymphatic cholesterol absorption of a corresponding control non-human mammal indicates said compound does not inhibit lymphatic absorption of cholesterol.

31. The method of claim 30, wherein said known amount of cholesterol and said compound are administered in a lipid emulsion.

32. The method of claim 30, wherein said non-human mammal is a rat.

33. The method of claim 32, wherein said non-human mammal is fasted prior to said administering step.

34. A composition comprising a compound of Formula 1:.

35. The composition of claim 34, wherein said at least one pharmaceutically-acceptable carrier material is selected from the group consisting of lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, povidone, polyvinylpyrrolidone, and polyvinyl alcohol.

36. The composition of claim 34, wherein said composition is in the form of a capsule or a liquid emulsion.

37. The composition of claim 34, wherein said composition is provided in a controlled release formulation.

38. The composition of claim 37, wherein said composition is provided as a dispersion in hydroxypropylmethylcellulose.

39. The composition of claim 34, wherein said composition is in a formulation suitable for parenteral administration.

40. The composition of claim 39, wherein said formulation is a lipid emulsion.

41. The composition of claim 34, wherein said composition comprises a diluent selected from the group consisting of polyethylene glycol, propylene glycol, cottonseed oil, peanut oil, sesame oil, and benzyl alcohol.

42. A method of treating a cholesterol-related condition, comprising administering an effective amount of a compound of Formula 1 to a mammal.

43. The method of claim 42, wherein said cholesterol-related condition is selected from the group consisting of atherosclerosis, hypercholesterolemia, heart attack, gangrene, and stroke.

44. The method of claim 42, wherein said cholesterol-related condition is selected from the group consisting of atherosclerosis, hypercholesterolemia, heart attack, gangrene, and stroke.

45. The method of claim 42, wherein said compound is administered orally, intravenously, intraperitoneally, subcutaneously, intramuscularly, or topically.

46. The method of claim 42, wherein said compound is administered in an amount from about 4 mg/kg to about 4 g/kg of body weight per day.

47. The method of claim 42, wherein said compound is administered as part of a treatment regimen comprising a diet low in cholesterol.

48. The method of claim 42, wherein said compound is administered as part of a treatment regimen comprising one or more HMG-CoA reductase inhibitors.

49. The method of claim 42, wherein said compound is administered for 7 days or more.

50. The method of claim 49, wherein said compound is administered for one year or more.

51. The method of claim 48, wherein said compound is administered in an amount from about 4 mg/kg body weight to about 4 g/kg body weight per day.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,
Item [75], Inventors, please delete “Wrillimantic” and insert -- Willimantic -- therefor; and please delete “US” and insert -- Korea -- therefor;
Item [56], References Cited, OTHER PUBLICATIONS, “Hamann and Scheuer” reference, please delete “Sesquitepene” and insert -- Sesquiterpene -- therefor.

Signed and Sealed this

Fourth Day of January, 2005

JON W. DUDAS
Director of the United States Patent and Trademark Office